PT  - JOURNAL ARTICLE
AU  - Haddad, Natalie S.
AU  - Nozick, Sophia
AU  - Kim, Geena
AU  - Ohanian, Shant
AU  - Kraft, Colleen S.
AU  - Rebolledo, Paulina A.
AU  - Wang, Yun
AU  - Wu, Hao
AU  - Bressler, Adam
AU  - Thi Le, Sang Nguyet
AU  - Kuruvilla, Merin
AU  - Cannon, L. Edward
AU  - Lee, F. Eun-Hyung
AU  - Daiss, John L.
TI  - Antibodies in Serum and MENSA Predict Non-recurrence in Primary <em>Clostridioides difficile</em> infection
AID  - 10.1101/2021.11.04.21265901
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.04.21265901
4099  - http://medrxiv.org/content/early/2021/11/04/2021.11.04.21265901.short
4100  - http://medrxiv.org/content/early/2021/11/04/2021.11.04.21265901.full
AB  - Background Within eight weeks of primary Clostridioides difficile infection (CDI), as many as 30% of patients develop recurrent disease with the associated risks of multiple relapses, morbidity, and economic burden. There are no validated biomarkers predictive of recurrence during primary infection. This study demonstrates the potential of a simple test for identifying hospitalized CDI patients at low risk for disease recurrence.Methods Forty-six hospitalized CDI patients were enrolled at Emory University Hospitals. Serum and MENSA samples prepared during weeks 1, 2, and 4 following symptom-onset were measured for antibodies specific for ten C. difficile antigens.Results Among the 46 C. difficile-infected patients, nine (19.5%) experienced recurrence within eight weeks of primary infection. Among the 37 non-recurrent patients, 23 had anti-C. difficile MENSA antibodies specific for any of the three toxin antigens: TcdB-CROP, TcdBvir-CROP, and/or CDTb. Positive MENSA responses occurred within the first week post-symptom onset, including six patients who never seroconverted. A similar trend was observed in serum responses, but they peaked later and identified fewer patients (19/37). In contrast, none of the patients who subsequently recurred after hospitalization produced antibodies specific for the three C. difficile toxin antigens. IgA antibodies for the toxin antigens demonstrated the greatest predictive power for protection from recurrence.Discussion The development of IgG and/or IgA antibodies for three C. difficile toxins in serum and/or MENSA has prognostic potential. These immunoassays measure nascent immune responses that reduce the likelihood of recurrence. Early identification of patients at-risk for recurrence can reduce costs and morbidity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Centers for Disease Control and Prevention through Research Contract #200-2015-88233 titled Antibody Secreting Cells (ASC) in Human Clostridium difficile Infection, Colonization, and Recurrence.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Emory and Dekalb Institutional Review Boards and the Grady Research Oversight Committee approved all protocols and procedures. Written informed consent was obtained from each patient prior to inclusion in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors